母亲大麻使用、不良妊娠结局与新生儿发病率
本研究为死胎协作研究网络队列中单胎活产对照的二次分析,用自我报告和/或脐带匀浆中11-去甲-δ-9-四氢大麻酚-9-羧酸检测评估母亲大麻使用。大麻使用与复合不良妊娠结局无关,但与复合新生儿发病率或死亡风险升高相关。
要点
- 母亲大麻使用率为2.7%(未加权频数48/1610)。
- 大麻使用与复合不良妊娠结局无关(校正比值比1.29,95%CI 0.56-2.96)。
- 大麻使用与复合新生儿发病率或死亡相关(校正比值比3.11,95%CI 1.40-6.91)。
核心结论
- 母亲大麻使用与小于胎龄儿、自发性早产或妊娠期高血压疾病的复合结局无关,但与新生儿发病率风险升高相关。
研究设计与样本
- 对死胎协作研究网络数据集中单胎活产对照的二次分析。
- 大麻使用由自我报告和/或脐带匀浆中11-去甲-δ-9-四氢大麻酚-9-羧酸检测界定。
- 采用加权方法分析,以校正原研究的过采样。
主要发现
- 母亲大麻使用见于2.7%活产(未加权频数48/1610),自我报告1.6%(34/1610),脐带匀浆检测1.9%(17/897),n=3重叠。
- 烟草使用率为12.9%(217/1610),自我报告10.7%(167/1607),血清可替宁9.5%(141/1313)。
- 复合不良妊娠结局在大麻使用者与非使用者间无显著增加(31.2% vs 21.2%;P=0.14)。
- 校正烟草、临床和社会经济因素后,大麻使用与复合不良妊娠结局无关(校正比值比1.29;95%CI 0.56-2.96)。
- 在具备脐带匀浆和血清可替宁数据的妇女中(n=765),大麻使用与不良妊娠结局无关(校正比值比1.02;95%CI 0.18-5.66)。
关键数值与推荐
- 新生儿重症监护室入住率在组间无统计学差异(使用者16.9% vs 非使用者9.5%,P=0.12)。
- 复合新生儿发病率或死亡在大麻使用母亲的新生儿中更常见(14.1% vs 4.5%;P=0.002)。
- 单变量比较中,大麻使用者新生儿的感染发病率(9.8% vs 2.4%;P<0.001)和神经系统发病率(1.4% vs 0.3%;P=0.002)更常见。
- 校正烟草、种族和其他非法药物使用后,大麻使用仍与复合新生儿发病率或死亡相关(校正比值比3.11;95%CI 1.40-6.91)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Eunice Kennedy Shriver National Institute of Child Health and Human Development Stillbirth Collaborative Research Network previously demonstrated an association between stillbirth and maternal marijuana use as defined by the presence of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in the umbilical cord homogenate. However, the relationship between marijuana use and perinatal complications in live births is uncertain. OBJECTIVE: Our aim was to examine if maternal marijuana use is associated with increased odds of adverse pregnancy outcomes and neonatal morbidity among live-born controls in the Stillbirth Collaborative Research Network cohort. STUDY DESIGN: We conducted a secondary analysis of singleton, live-born controls in the Stillbirth Collaborative Research Network data set. Marijuana use was measured by self-report and/or the presence of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in umbilical cord homogenate. Tobacco use was measured by self-report and/or presence of any cotinine in maternal serum. Adverse pregnancy outcome was a composite of small for gestational age, spontaneous preterm birth resulting from preterm labor with or without intact membranes, and hypertensive disorders of pregnancy. Neonatal morbidity included neonatal intensive care unit admission and composite neonatal morbidity (pulmonary morbidity, necrotizing enterocolitis, seizures, retinopathy of prematurity, infection morbidity, anemia requiring blood transfusion, neonatal surgery, hyperbilirubinemia, neurological morbidity, or death prior to hospital discharge). Effect of maternal marijuana use on the probability of an adverse outcome was estimated using weighted methodology to account for oversampling in the original study. 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid cord homogenate analysis was performed in the subset of women for whom biospecimens were available. Comparisons using logistic modeling, χ2, and t tests were weighted to account for oversampling of preterm births and non-Hispanic blacks. Results are reported as weighted percent and unweighted frequencies. RESULTS: Maternal marijuana use was identified in 2.7% (unweighted frequency 48/1610) of live births. Use was self-reported by 1.6% (34/1610) and detected by 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in cord homogenate for 1.9% (17/897), n = 3 overlapping. Rate of tobacco use was 12.9% (217/1610), with 10.7% (167/1607) by self-report and 9.5% (141/1313) by serum cotinine. The composite adverse pregnancy outcome was not significantly increased in women with marijuana use compared to nonusers (31.2% vs 21.2%; P = .14). After adjustment for tobacco, clinical, and socioeconomic factors, marijuana use was not associated with the composite adverse pregnancy outcome (adjusted odds ratio, 1.29; 95% confidence interval, 0.56-2.96). Similarly, among women with umbilical cord homogenate and serum cotinine data (n = 765), marijuana use was not associated with adverse pregnancy outcomes (adjusted odds ratio, 1.02; 95% confidence interval, 0.18-5.66). Neonatal intensive care unit admission rates were not statistically different between groups (16.9% users vs 9.5% nonusers, P = .12). Composite neonatal morbidity or death was more frequent among neonates of mothers with marijuana use compared to nonusers (14.1% vs 4.5%; P = .002). In univariate comparisons, the components of the composite outcome that were more frequent in neonates of marijuana users were infection morbidity (9.8% vs 2.4%; P < .001) and neurologic morbidity (1.4% vs 0.3%; P = .002). After adjustment for tobacco, race, and other illicit drug use, marijuana use was still associated with composite neonatal morbidity or death (adjusted odds ratio, 3.11; 95% confidence interval, 1.40-6.91). CONCLUSION: Maternal marijuana use was not associated with a composite of small for gestational age, spontaneous preterm birth, or hypertensive disorders of pregnancy. However, it was associated with an increased risk of neonatal morbidity.
引用
- Metz TD, Allshouse AA, Hogue CJ, et al. Maternal marijuana use, adverse pregnancy outcomes, and neonatal morbidity. Am J Obstet Gynecol. 2017. PMID: 28578174. doi:10.1016/j.ajog.2017.05.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。